Michael Schultz

Schultz, Mike Michael
Associate Professor of Radiology-Division of Nuclear Medicine
Associate Professor (Secondary Appointment) of Chemistry
Phone: 
319-335-8017
Office: 
B180 ML
Biosketch: 

Michael K. Schultz, PhD, is an Associate Professor of Radiology, Pediatrics, Chemistry and Radiation Oncology (Free Radical and Radiation Biology Program) at The University of Iowa. Dr. Schultz's lab focuses on tumor cell biology, radiation biology, peptide based ligand development, and radiochemistry for the development of image-guided radionuclide based therapies for cancer. The lab focuses on NETs, related pediatric brain tumors, and metastatic melanoma. With underlying support from the NET SPORE (PI M. Sue O'Dorisio MD PhD). Dr. Schultz's lab is laying a foundation for alpha particle targeted therapy for these cancers through three basic initiatives supported by the NET SPORE and other NIH/NCI funding. (1) Image-guided peptide theranostic development; (2) Enhanced dosimetry modeling focused on alpha particle interactions in the tumor microenvironment; and (3) Radiopharmaceutical production automation for theranostic agents. The lab is focused on the theranostic pair of radionuclides 203Pb for SPECT imaging and 212Pb for alpha + beta particle therapy for cancer. (4) Oxidative metabolism and the role of mitochondrial ROS metabolism in the acquisition of resistance to cancer chemotherapies with a focus on the relationships between ROS metabolism, ER stress, autophagic flux, and acquisition of resistance.

For synopses of these projects and more information about Dr. Schultz's research and academic activities, please visit the Schultz Lab website.

Recent Publications: 
  • Menda, Y., Madsen, M. T., O'Dorisio, T. M., Sunderland, J., Watkins, L. G., Dillon, J. S., Mott, S. L., Schultz, M. K., Zamba GKD, Bushnell, D. L. & O'Dorisio, M. S. (2018). 90Y-DOTATOC Dosimetry-Based Personalized Peptide Receptor Radionuclide Therapy. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. PMID: 29523629. DOI: 10.2967/jnumed.117.202903.
  • Rosenblum, J., Nelson, A. W., Ruyle, B., Schultz, M. K., Linden, K. G. & Ryan, J. N. (2017). Temporal characterization of flowback and produced water quality from a hydraulically fractured oil and gas well. The Science of the total environment 596-597 369-377. PMID: 28448913. DOI: 10.1016/j.scitotenv.2017.03.294.
  • Li, M., Zhang, X., Quinn, T. P., Lee, D., Liu, D., Kunkel, F., Zimmerman, B. E., McAlister, D., Olewein, K., Menda, Y., Mirzadeh, S., Copping, R., Johnson, F. L. & Schultz, M. K. (2017). Automated cassette-based production of high specific activity [203/212Pb]peptide-based theranostic radiopharmaceuticals for image-guided radionuclide therapy for cancer. Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine 127 52-60. PMID: 28521118. DOI: 10.1016/j.apradiso.2017.05.006.
  • Menda, Y., O'Dorisio, T. M., Howe, J. R., Schultz, M., Dillon, J. S., Dick, D., Watkins, G. L., Ginader, T., Bushnell, D. L., Sunderland, J. J., Zamba GKD, Graham, M. & O'Dorisio, M. S. (2017). Localization of Unknown Primary Site with 68Ga-DOTATOC PET/CT in Patients with Metastatic Neuroendocrine Tumor. Journal of nuclear medicine : official publication, Society of Nuclear Medicine 58 (7) 1054-1057. PMID: 28153957. DOI: 10.2967/jnumed.116.180984.
  • May, D., Nelson, A. N. & Schultz, M. K. (2017). Quantitation of lead-210 (210Pb) using lead-203 (203Pb) as a "Massless" yield tracer. Journal of environmental radioactivity 171 93-98. PMID: 28213127. DOI: 10.1016/j.jenvrad.2017.02.003.
  • Schoenfeld, J. D., Sibenaller, Z. A., Mapuskar, K. A., Wagner, B. A., Cramer-Morales, K. L., Furqan, M., Sandhu, S., Carlisle, T. L., Smith, M. C., Abu Hejleh, T., Berg, D. J., Zhang, J., Keech, J., Parekh, K. R., Bhatia, S., Monga, V., Bodeker, K. L., Ahmann, L., Vollstedt, S., Brown, H., Shanahan Kauffman, E. P., Schall, M. E., Hohl, R. J., Clamon, G. H., Greenlee, J. D., Howard, M. A., Schultz, M. K., Smith, B. J., Riley, D. P., Domann, F. E., Cullen, J. J., Buettner, G. R., Buatti, J. M., Spitz, D. R. & Allen, B. G. (2017). O2·- and H2O2-Mediated Disruption of Fe Metabolism Causes the Differential Susceptibility of Lung and Brain Cancer Cells to Pharmacological Ascorbate. Cancer cell 31 (4) 487-500.e8. PMID: 28366679. DOI: 10.1016/j.ccell.2017.02.018.
  • (Eds.) (2013). Theranostics, gallium-68, and other radionuclides: a pathway to personalized diagnosis and treatment. J Nucl Med. 54 (4) 659-60.
  • Menda, Y., Ponto, L. L., Schultz, M. K., Zamba, G. K., Watkins, G. L., Bushnell, D. L., Madsen, M. T., Sunderland, J. J., Graham, M. M., O'Dorisio, T. M. & O'Dorisio, M. S. (2013). Repeatability of Gallium-68 DOTATOC Positron Emission Tomographic Imaging in Neuroendocrine Tumors. Pancreas. PMID: 23587853.
  • Menda, Y., Boles Ponto, L. L., Schultz, M. K., D. Zamba, G. K., Watkins, G. L., Bushnell, D. L., Madsen, M. T., Sunderland, J. J., Graham, M. M., O’Dorisio, T. M. & O’Dorisio, M. S. (2013). Repeatability of Ga-68 DOTATOC PET Imaging in Neuroendocrine Tumors. Pancreas.
  • Martin, M. E., Sue O'Dorisio, M., Leverich, W. M., Kloepping, K. C., Walsh, S. A. & Schultz, M. K. (2013). Click-cyclized (68)Ga-labeled peptides for molecular imaging and therapy: synthesis and preliminary in vitro and in vivo evaluation in a melanoma model system. Recent results in cancer research. Fortschritte der Krebsforschung. Progrès dans les recherches sur le cancer 194 149-75. PMID: 22918759.